Tumor-infiltrating podoplanin<sup>+</sup> cells in gastric cancer: clinical outcomes and association with immune contexture.

Oncoimmunology · 2020 · PMC7671044 · PMID 33235820

Europe PMC DOI

hedged sentence

0.0830

closest p · 1.7× alpha

0.0830

boldest claim

The sentences

showed a trendP = .083so close (0.05 < p ≤ 0.1)

Contrarily, in tPDPNs high subgroup, receiving ACT just showed a trend toward OS improvement, while could not predict DFS benefits ( P = .083 and P = .536; Figure 3c ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.